Top Financing Of 2016: Cast Your Vote!
Executive Summary
It's time once again for In Vivo's Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
In Vivo's Top Financing Of 2016 –The Nominees Are:
Another Big Round For Moderna: The $474 million equity financing that the mRNA drug developer raised in September will cover R&D, manufacturing and pipeline expansion costs until it has proof-of-concept data in hand and can go public. [See Deal]
Grail Spins Out Of Illumina: In January, liquid biopsy play Grail Bio raised a $100 million-plus Series A round from top-flight investors, including majority owner Illumina. In December, Grail announced it's on the hunt for another $1.7 billion to fund a clinical trial in half a million people. [See Deal]
Corporate Venture Bolsters Akili: Merck Ventures and Amgen Ventures participated in Akili Interactive Labs' $42 million multi-tranche Series B round in 2016. The proceeds will fuel development of Akili's clinically-validated video game for assessing and treating cognitive disorders. [See Deal]
Samsung BioLogics' $2 Billion IPO: The November IPO, the third largest in South Korea's history, is a big validation for biologics development in that country and also shows the importance of diversification for parent Samsung. [See Deal]
DalCor Pharma Gets $100 Million For CETP Inhibitor: Hoping for better luck than its big pharma counterparts have had with CETP inhibitors, Dalcor closed a $100 million Series B round to fund Phase III trials of dalcetrapib (licensed from Roche, which terminated it for lack of efficacy) in a genetically distinct group of patients with acute coronary syndrome. [See Deal]
CLICK HERE To Cast Your Vote For The Most Significant Financing Of 2016
CLICK HERE to Cast Your Vote For The Most Significant Strategic Alliance Of 2016
Coming Up Next In IVDOTY16: Top M&A